Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone furoate + umeclidinium is a fixed-dose combination of two inhaled medications used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Fluticasone furoate is an inhaled corticosteroid (ICS) that reduces inflammation in the airways, while umeclidinium is a long-acting muscarinic antagonist (LAMA) that acts as a bronchodilator by blocking muscarinic receptors in airway smooth muscle, leading to relaxation and improved airflow. This combination may be used alone or as part of triple therapy with vilanterol for COPD management[5][8]. The primary indication is long-term maintenance treatment to improve breathing and reduce exacerbations in COPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluticasone furoate + umeclidinium.